The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19
Copyright © 2021 Elsevier B.V. All rights reserved..
The coronavirus disease (COVID-19) has once again reminded us of the significance of host immune response and consequential havocs of the immune dysregulation. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) inflicts severe complications to the infected host, including cough, dyspnoea, fever, septic shock, acute respiratory distress syndrome (ARDs), and multiple organ failure. These manifestations are the consequence of the dysregulated immune system, which gives rise to excessive and unattended production of pro-inflammatory mediators. Elevated circulatory cytokine and chemokine levels are accompanied by spontaneous haemorrhage, thrombocytopenia and systemic inflammation, which are the cardinal features of life-threatening cytokine storm syndrome in advanced COVID-19 diseases. Coronavirus hijacked NF-kappa B (NF-κB) is responsible for upregulating the expressions of inflammatory cytokine, chemokine, alarmins and inducible enzymes, which paves the pathway for cytokine storm. Given the scenario, the systemic approach of simultaneous inhibition of NF-κB offers an attractive therapeutic intervention. Targeted therapies with proteasome inhibitor (VL-01, bortezomib, carfilzomib and ixazomib), bruton tyrosine kinase inhibitor (acalabrutinib), nucleotide analogue (remdesivir), TNF-α monoclonal antibodies (infliximab and adalimumab), N-acetylcysteine and corticosteroids (dexamethasone), focusing the NF-κB inhibition have demonstrated effectiveness in terms of the significant decrease in morbidity and mortality in severe COVID-19 patients. Hence, this review highlights the activation, signal transduction and cross-talk of NF-κB with regard to cytokine storm in COVID-19. Moreover, the development of therapeutic strategies based on NF-κB inhibition are also discussed herein.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
---|---|
Enthalten in: |
International immunopharmacology - 101(2021), Pt B vom: 15. Dez., Seite 108255 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Attiq, Ali [VerfasserIn] |
---|
Links: |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
Date Completed 20.12.2021 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.intimp.2021.108255 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM332282635 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM332282635 | ||
003 | DE-627 | ||
005 | 20231225215254.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.intimp.2021.108255 |2 doi | |
028 | 5 | 2 | |a pubmed24n1107.xml |
035 | |a (DE-627)NLM332282635 | ||
035 | |a (NLM)34688149 | ||
035 | |a (PII)S1567-5769(21)00891-2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Attiq, Ali |e verfasserin |4 aut | |
245 | 1 | 4 | |a The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19 |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 20.12.2021 | ||
500 | |a Date Revised 21.12.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
520 | |a The coronavirus disease (COVID-19) has once again reminded us of the significance of host immune response and consequential havocs of the immune dysregulation. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) inflicts severe complications to the infected host, including cough, dyspnoea, fever, septic shock, acute respiratory distress syndrome (ARDs), and multiple organ failure. These manifestations are the consequence of the dysregulated immune system, which gives rise to excessive and unattended production of pro-inflammatory mediators. Elevated circulatory cytokine and chemokine levels are accompanied by spontaneous haemorrhage, thrombocytopenia and systemic inflammation, which are the cardinal features of life-threatening cytokine storm syndrome in advanced COVID-19 diseases. Coronavirus hijacked NF-kappa B (NF-κB) is responsible for upregulating the expressions of inflammatory cytokine, chemokine, alarmins and inducible enzymes, which paves the pathway for cytokine storm. Given the scenario, the systemic approach of simultaneous inhibition of NF-κB offers an attractive therapeutic intervention. Targeted therapies with proteasome inhibitor (VL-01, bortezomib, carfilzomib and ixazomib), bruton tyrosine kinase inhibitor (acalabrutinib), nucleotide analogue (remdesivir), TNF-α monoclonal antibodies (infliximab and adalimumab), N-acetylcysteine and corticosteroids (dexamethasone), focusing the NF-κB inhibition have demonstrated effectiveness in terms of the significant decrease in morbidity and mortality in severe COVID-19 patients. Hence, this review highlights the activation, signal transduction and cross-talk of NF-κB with regard to cytokine storm in COVID-19. Moreover, the development of therapeutic strategies based on NF-κB inhibition are also discussed herein | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Cytokine storm | |
650 | 4 | |a Inflammation | |
650 | 4 | |a NF-κB | |
650 | 4 | |a Novel coronavirus | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a Severe acute respiratory syndrome | |
650 | 7 | |a Gonadal Steroid Hormones |2 NLM | |
650 | 7 | |a NF-kappa B |2 NLM | |
700 | 1 | |a Yao, Lui Jin |e verfasserin |4 aut | |
700 | 1 | |a Afzal, Sheryar |e verfasserin |4 aut | |
700 | 1 | |a Khan, Mansoor Ali |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 101(2021), Pt B vom: 15. Dez., Seite 108255 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
773 | 1 | 8 | |g volume:101 |g year:2021 |g number:Pt B |g day:15 |g month:12 |g pages:108255 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2021.108255 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 101 |j 2021 |e Pt B |b 15 |c 12 |h 108255 |